{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-028529","form_type":"8-K","ticker":"ABCL","cik":"0001703057","company_name":"AbCellera Biologics Inc.","filed_at":"2025-05-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.399499+00:00","generated_at":"2026-05-20T04:32:28.057825+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AbCellera receives Health Canada authorization for Phase 1 trial of ABCL575 for atopic dermatitis","bullets":["Health Canada issued No Objection Letter authorizing Clinical Trial Application for ABCL575, an anti-OX40L antibody.","ABCL575 is an Fc-silenced, half-life extended investigational antibody for moderate-to-severe atopic dermatitis.","Phase 1 trial anticipated to start in Q3 2025, evaluating safety and pharmacokinetics in healthy participants."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-028529","json":"https://secwatch.observer/filing/0001628280-25-028529.json","markdown":"https://secwatch.observer/filing/0001628280-25-028529.md","text":"https://secwatch.observer/filing/0001628280-25-028529.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703057/000162828025028529/0001628280-25-028529-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703057/000162828025028529/abcl-20250530.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T04:32:28.057825+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}